Form 8-K - Current report:
SEC Accession No. 0001558370-24-015632
Filing Date
2024-11-14
Accepted
2024-11-14 09:17:26
Documents
16
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pmn-20241114x8k.htm   iXBRL 8-K 37720
2 EX-99.1 pmn-20241114xex99d1.htm EX-99.1 194875
3 GRAPHIC pmn-20241114xex99d1001.jpg GRAPHIC 6463
  Complete submission text file 0001558370-24-015632.txt   389963

Data Files

Seq Description Document Type Size
4 EX-101.SCH pmn-20241114.xsd EX-101.SCH 4052
5 EX-101.DEF pmn-20241114_def.xml EX-101.DEF 2876
6 EX-101.LAB pmn-20241114_lab.xml EX-101.LAB 17911
7 EX-101.PRE pmn-20241114_pre.xml EX-101.PRE 11842
18 EXTRACTED XBRL INSTANCE DOCUMENT pmn-20241114x8k_htm.xml XML 5094
Mailing Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2
Business Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2 416-847-6898
ProMIS Neurosciences Inc. (Filer) CIK: 0001374339 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41429 | Film No.: 241457694
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)